

PCM

PRECISION CANCER MEDICINE


A JOURNAL AIMING TO DELIVER A LASTING BLOW TO CANCER

PCM Annual Report 2022

Editorial Office pcm@amegroups.com




复旦大学附属肿瘤医院
Fudan University Shanghai Cancer Center



Outline of the Report

1. Basic Information
2. Geographic Distribution of Editorial Board Members (2022)
3. Number of Articles Published (Results by Year, 2018 - 2022)
4. Diverse Types of Articles Published in 2022
5. Geographic Distribution of Corresponding Authors in 2022
6. Website Pageviews (Results by Year, 2018 - 2022)
7. Website Users (Results by Year, 2018 - 2022)
8. Geographic Distribution of Website Users in 2022
9. Top 10 Most Read Articles in 2022
10. Special Series (Ongoing)
11. PCM Chinese Edition
12. Interviews with Outstanding Authors (2022)
13. Reviewer of the Month (2022)



1. Basic Information

Precision Cancer Medicine (PCM, Precis Cancer Med, ISSN: 2617-2216)

- An open access, peer-reviewed online journal
- Launched in April 2018
- Included in Scopus since June 2021
- The official journal of Fudan University Shanghai Cancer Center
- Dedicated to precise diagnosis and treatment of cancers and personalized care for patients
- To explore different kinds of cancers and encompass various areas of oncology, pathology, imaging, radiotherapy, chemotherapy, surgery, anesthesiology, nursing and etc.



1. Basic Information

Editor-in-Chief

Xiaomao Guo, MD


Professor, Fudan University,
President, Fudan University Shanghai Cancer Center,
President, Shanghai Proton and Heavy Ion Center,
Shanghai, China



Executive Editor-in-Chief


Zhimin Shao, MD

Professor, Fudan University,
Director, Fudan University Cancer Institute and Breast
Cancer Institute,
Fudan University Shanghai Cancer Center,
Shanghai, China



“On behalf of the editorial team, we would like to express our heartfelt appreciation to all the editorial board members, guest editors, reviewers, and authors for your support and contributions to the steady growth of PCM in 2022.


In the new year of 2023, we look forward to your continued joint efforts in advancing knowledge and research in the field of precision cancer research.”



Xiaomao Guo, MD
Editor-in-Chief, PCM




Zhimin Shao, MD
Executive Editor-in-Chief, PCM




2. Geographic Distribution of Editorial Board Members (2022)


Editorial Board Members by Country
% of total: 100% (211 Members from 18 Countries)




PCM has built an internationalized editorial board of 211 members from 18 countries, with the largest proportion from USA (31%), followed by Italy (18%), China (11%) Spain (9%), France (6%), etc.




3. Number of Articles Published (Results by Year, 2018 - 2022)



The articles published in PCM have remained stable, with a total number of 175 since its launch in 2018.



4. Diverse Types of Articles Published in 2022



A total of 40 articles were published in 2022, including:


| | |
|------------------------|----|
| Review Article | 17 |
| Case Report | 10 |
| Editorial (Commentary) | 7 |
| Original Article | 4 |
| Expert Consensus | 1 |
| Study Protocol | 1 |




5. Geographic Distribution of Corresponding Authors in 2022

Authors by Country


% of total: 100% (40 authors from 14 countries)



A total of 40 corresponding authors were identified in 2022, with the largest percentage from Italy (37%), followed by USA (15%), China (10%), Spain (7%), Canada (5%), etc.



6. Website Pageviews (Results by Year, 2018 - 2022)




* Website pageviews of PCM have continued to increase since its launch in 2018.

* The total number of pageviews has reached 253,584 by 2022.

Data collected from Google Analytics on Jan 6, 2023




7. Website Users (Results by Year, 2018 - 2022)














* Website users of PCM have continued to rise since its launch in 2018.

* The total number of users has reached 86,244 by 2022.

Data collected from Google Analytics on Jan 6, 2023




8. Geographic Distribution of Website Users in 2022

| Country | Users | Users | Contribution to total: |
|---|---|---|--|
| | 35,663 % of Total: 100.00% (35,663) | 35,663 % of Total: 100.00% (35,663) | |
| 1.  United States | 13,516 | 37.58% |  |
| 2.  China | 2,806 | 7.80% | |
| 3.  India | 2,378 | 6.61% | |
| 4.  United Kingdom | 2,201 | 6.12% | |
| 5.  Italy | 1,506 | 4.19% | |
| 6.  Canada | 1,476 | 4.10% | |
| 7.  South Korea | 803 | 2.23% | |
| 8.  Germany | 792 | 2.20% | |
| 9.  Japan | 733 | 2.04% | |
| 10.  Australia | 730 | 2.03% | |

* Totally 35,663 website users from 152 countries were identified in 2022.

* USA was the most represented country with 37.6% of the total users.

Data collected from Google Analytics on Jan 6, 2023



9. Top 10 Most Read Articles in 2022

| No. | Pub. Time | Article Type | Article Title | Corresponding Author | Pageviews |
|-----|-----------|----------------------|--|---------------------------|-----------|
| 1 | Dec 2021 | Original Article | Comparison of cancer incidence and mortality between China and the United States | Ying Zheng (China) | 3,725 |
| 2 | Mar 2022 | Review Article | Role of radiation therapy in triple negative breast cancer: current state and future directions—a narrative review | Joelle Helou (Canada) | 2,438 |
| 3 | Sep 2021 | Review Article | ROS1 non-small cell lung cancer patients treatment approach | Eduar Arriola (Spain) | 1,972 |
| 4 | Mar 2020 | Review Article | Non-small cell lung cancer PDL1 >50%—should we go single or combo? | Nir Peled (Israel) | 1,157 |
| 5 | Jun 2020 | Case Report | Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond? | Daniel B. Costa (USA) | 1,090 |
| 6 | Jun 2021 | Editorial Commentary | PARP inhibitors beyond BRCA-mutated cancers: precision medicine at the crossroads | Jacek Jassem (Poland) | 1,060 |
| 7 | Mar 2020 | Review Article | Non-small cell lung cancer targetable mutations: present and future | Peter Vu (USA) | 957 |
| 8 | Dec 2021 | Review Article | A narrative review of microRNA therapeutics: understanding the future of microRNA research | Xianghuo He (China) | 808 |
| 9 | Jun 2021 | Review Article | A narrative review of chemotherapy in advanced triple negative breast cancer | Rossanna C. Pezo (Canada) | 784 |
| 10 | Jul 2018 | Editorial | Diffuse large B-cell lymphoma with molecular variations more than ABC and GCB classification | Ken H. Young (USA) | 726 |




10. Special Series (Ongoing)

(1) [Quality Assurance in Radiotherapy](#)

Guest Editors:

Paul Van Houtte & Dirk Van Gestel

(Institut Jules Bordet, Université Libre de Bruxelles, Belgium)



10. Special Series (Ongoing)

(2) [Lung Cancer In Women: From Epidemiology To Therapy](#)

Guest Editors:


Editta Baldini (San Luca Hospital, Italy);

Franca Melfi (University Hospital of Pisa, Italy)



(3) [Uncommon Mutations in Non-Small Cell Lung Cancer](#)

Guest Editor: Marco Russano (University Campus Bio-Medico of Rome, Italy)



10. Special Series (Ongoing)

(4) [How to Detect and Treat NSCLC Patients with Oncogenic Fusions](#)

Guest Editors:

Fabrizio Tabbò (University of Turin, Italy) ;


Umberto Malapelle (University of Naples Federico II, Italy) ;

Maria Lucia Reale (University of Turin, Italy) ;

Angela Listì (University of Turin, Italy)



FABRIZIO TABBÒ; UMBERTO MALAPELLE; MARIA LUCIA REALE; ANGELA LISTÌ




10. Special Series (Ongoing)

(5) [Predictive and Prognostic Biomarkers in Tumors](#)

Guest Editors:

Mari Mino-Kenudson (Massachusetts General Hospital, USA);


Yin (Rex) P. Hung (Massachusetts General Hospital, USA)



(6) [Management of Triple Negative Breast Cancer](#)

Guest Editor:

Jacques Raphael, MD (Western University, Canada)



11. PCM Chinese Edition

PCM PRECISION CANCER MEDICINE
A JOURNAL AIMING TO DELIVER A LASTING BLOW TO CANCER

Title

Full Text

Author

Search

Go

Advanced Search

Home

Journal Info

For Authors

For Reviewers

Ethics and Policies

Special Contents

Archives

Online First

Article Processing Charges

News

Home / PCM Chinese Edition

PCM Chinese Edition

The PCM Chinese edition (the Chinese edition of Precision Cancer Medicine) is a Chinese-language column that addresses the growing need for trusted medical information in China. The initiative of the PCM Chinese edition aims to raise awareness of medical advances among clinicians through translated content, enhancing the links between Chinese scientists and the international medical community.

The translation of a selection of full-text content from PCM applies rigorous standards to ensure accuracy and quality control. The PCM Chinese edition will deliver the quality clinical and scientific content to the Chinese medical and clinical research community.

早期三阴性乳腺癌免疫检查点抑制剂回顾

Posted on 2022-06-27 11:33:29

三阴性乳腺癌 (triple negative breast cancer, TNBC) 是一类缺乏雌激素受体、孕激素受体及表皮生长因子受体2 (human epidermal growth factor receptor 2, HER2) 表达的乳腺癌, 占所有乳腺癌的10%~15%。

Read more →

人类肿瘤中BRAF改变的叙述性综述: 诊断和预测意义

Posted on 2022-06-27 11:32:10

B-Raf原癌基因, 丝氨酸/苏氨酸激酶 (BRAF) 是人类肿瘤发生过程中最常见、最具特征性的癌基因之一。

Read more →

营养影响疾病的潜在分子机制

Posted on 2022-06-27 11:29:16

人体约有50至70万亿个细胞, 每个细胞都在高度复杂的生物系统网络中发挥着各自的功能。

Read more →


NTRK和NRG1基因融合在晚期非小细胞肺癌中的作用

Posted on 2022-06-27 11:28:14

基因重排是在实体瘤中发现的最常见的遗传异常之一, 具有越来越多的诊断和治疗意义。

Read more →


- Translation of a selection of full-text content from PCM
- Address the growing need for trusted medical information in China
- Raise awareness of medical advances among clinicians through translated content
- Enhance the links between Chinese scientists and the international medical community



12. Interviews with Outstanding Authors (2022)

This column [Interviews with Outstanding Authors \(2022\)](#) highlights some of our outstanding authors with a brief interview of their unique perspective and insightful view as authors.


Kiyotaka Yoh



Dr. Kiyotaka Yoh is the Assistant Chief of Thoracic Oncology at National Cancer Center Hospital East, Kashiwa, Japan. He graduated from Kumamoto University in 1997. After post-graduate residency, he received fellowship program of medical oncology in National Cancer Center Hospital East. His research interests include lung cancer treatment and early phase drug development. He has authored or co-authored more than 120 papers in SCI-indexed journals. He published "Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial" in The Lancet Respiratory Medicine in 2017. He is also a member of ASCO and ESMO.

To Dr. Yoh, a good academic paper should be original and scientifically reliable. In many cases, a research that one plans to do may have already been reported by others. Therefore, careful literature search of previous studies should be performed. Personally, Dr. Yoh prefers using PubMed for literature search. PubMed ushered in the era of private, free, home- and office-based MEDLINE searching since 1996. Other free search engines include Web of Science, Google Scholar and so on, which he often uses in his own research as well.

Data sharing is prevalent in scientific writing in recent years. In Dr. Yoh's opinion, data sharing is important but not necessary, because the research by original data still has the highest priority.



13. Reviewer of the Month (2022)


This column [Reviewer of the Month \(2022\)](#) highlight some of our outstanding reviewers, with a brief interview of their thoughts and insights as a reviewer.

Giuseppe Barisano



Dr. Giuseppe Barisano, M.D., Ph.D., is a physician-neuroscientist at the University of Southern California, Los Angeles (CA, USA). He obtained his medical degree with honors from San Raffaele University (Milan, Italy) and completed his Ph.D. in Neuroscience at the University of Southern California. His clinical interests include neuro-oncology, neurodegenerative disorders, and cerebrovascular diseases. During his Ph.D., he investigated the vascular contributions to neurodegeneration, with a focus on the role of perivascular spaces and blood-brain barrier damage. He studied and developed novel imaging approaches to investigate the cerebral vasculature using MRI in the context of physiological and pathological conditions. In his most recent work, he analyzed the changes occurring to cerebrospinal fluid and perivascular spaces of astronauts and cosmonauts after spaceflight. You may connect with Dr. Barisano on [Twitter](#) and [LinkedIn](#).

Peer review is critical for academic research because it allows not only to evaluate the significance and impact of a scientific work by experts in the field, but also to ensure that the technical aspects of the assessed project are valid, and the language and conclusions are appropriate and supported by the data presented. In numerous occasions, Dr. Barisano has noted that the suggestions provided by the reviewers contribute to significant improvement of the quality of the research articles.



Our Publisher

AME Publishing Company

- Established in 2009
- Registered in Hong Kong
- 10 offices around the world
- 60+ peer-reviewed journals
 - 13 indexed in SCIE
 - 7 indexed in ESCI
 - 20 indexed in PubMed/PMC/MEDLINE
- 200+ Medical Books
 - 80+ Medical Books in English
 - 120+ Medical Books in Chinese
- 150+ Electronic Editions





Thank you for all your support!

